TG THERAPEUTICS, INC. Right-of-Use Asset Obtained in Exchange for Operating Lease Liability
TG THERAPEUTICS, INC. (TGTX) reported Right-of-Use Asset Obtained in Exchange for Operating Lease Liability of $1.47 million for the 9-month period ending 2023-09-30, per its 10-Q filed 2023-11-06.
Discontinued › Notes › Leases
us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability · last filed 2023-11-06
- TG THERAPEUTICS, INC. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2023-09-30 was $483.00K, a 59.45% decline year-over-year.
- TG THERAPEUTICS, INC. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2023-06-30 was $499.00K, a 50.76% increase year-over-year.
- TG THERAPEUTICS, INC. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2023-03-31 was $491.00K, a 28.11% decline year-over-year.
- TG THERAPEUTICS, INC. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2022-12-31 was $510.00K, a 7.59% increase year-over-year.
- TG THERAPEUTICS, INC. right-of-use asset obtained in exchange for operating lease liability for fiscal 2022 was $2.71M, a 43.20% increase from fiscal 2021.
- TG THERAPEUTICS, INC. right-of-use asset obtained in exchange for operating lease liability for fiscal 2021 was $1.90M, a 18.45% decline from fiscal 2020.
- TG THERAPEUTICS, INC. right-of-use asset obtained in exchange for operating lease liability for fiscal 2020 was $2.33M, a 7.70% decline from fiscal 2019.
- TG THERAPEUTICS, INC. right-of-use asset obtained in exchange for operating lease liability for fiscal 2019 was $2.52M.
| Period end | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 3 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 6 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 9 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 12 month |
|---|---|---|---|---|
| 2023-09-30 | $483.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-06 | $982.00K derived: sum of 2 quarters · filed 2023-11-06 | $1.47M 10-Q · filed 2023-11-06 | $1.98M derived: sum of 4 quarters · filed 2023-11-06 |
| 2023-06-30 | $499.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-04 | $990.00K 10-Q · filed 2023-08-04 | $1.50M derived: sum of 3 quarters · filed 2023-08-04 | $2.69M derived: sum of 4 quarters · filed 2023-11-06 |
| 2023-03-31 | $491.00K 10-Q · filed 2023-05-08 | $1.00M derived: sum of 2 quarters · filed 2023-05-08 | $2.19M derived: sum of 3 quarters · filed 2023-11-06 | $2.52M derived: sum of 4 quarters · filed 2023-11-06 |
| 2022-12-31 | $510.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-01 | $1.70M derived: sum of 2 quarters · filed 2023-11-06 | $2.03M derived: sum of 3 quarters · filed 2023-11-06 | $2.71M 10-K · filed 2023-03-01 |
| 2022-09-30 | $1.19M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-06 | $1.52M derived: sum of 2 quarters · filed 2023-11-06 | $2.21M 10-Q · filed 2023-11-06 | $2.68M derived: sum of 4 quarters · filed 2023-11-06 |
| 2022-06-30 | $331.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-04 | $1.01M 10-Q · filed 2023-08-04 | $1.49M derived: sum of 3 quarters · filed 2023-08-04 | $1.96M derived: sum of 4 quarters · filed 2023-08-04 |
| 2022-03-31 | $683.00K 10-Q · filed 2023-05-08 | $1.16M derived: sum of 2 quarters · filed 2023-05-08 | $1.63M derived: sum of 3 quarters · filed 2023-05-08 | $2.10M derived: sum of 4 quarters · filed 2023-05-08 |
| 2021-12-31 | $474.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-01 | $947.00K derived: sum of 2 quarters · filed 2023-03-01 | $1.42M derived: sum of 3 quarters · filed 2023-03-01 | $1.90M 10-K · filed 2023-03-01 |
| 2021-09-30 | $473.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-09 | $943.00K derived: sum of 2 quarters · filed 2022-11-09 | $1.42M 10-Q · filed 2022-11-09 | $2.38M derived: sum of 4 quarters · filed 2023-03-01 |
| 2021-06-30 | $470.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-09 | $949.00K 10-Q · filed 2022-08-09 | $1.91M derived: sum of 3 quarters · filed 2023-03-01 | $819.00K derived: sum of 4 quarters · filed 2023-03-01 |
| 2021-03-31 | $479.00K 10-Q · filed 2022-05-10 | $1.44M derived: sum of 2 quarters · filed 2023-03-01 | $349.00K derived: sum of 3 quarters · filed 2023-03-01 | $803.00K derived: sum of 4 quarters · filed 2023-03-01 |
| 2020-12-31 | $961.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-01 | -$130.00K derived: sum of 2 quarters · filed 2023-03-01 | $324.00K derived: sum of 3 quarters · filed 2023-03-01 | $2.33M 10-K · filed 2023-03-01 |
| 2020-09-30 | -$1.09M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-08 | -$637.00K derived: sum of 2 quarters · filed 2021-11-08 | $1.36M 10-Q · filed 2021-11-08 | $1.96M derived: sum of 4 quarters · filed 2022-03-01 |
| 2020-06-30 | $454.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-06 | $2.46M 10-Q · filed 2021-08-06 | $3.05M derived: sum of 3 quarters · filed 2022-03-01 | $4.07M derived: sum of 4 quarters · filed 2022-03-01 |
| 2020-03-31 | $2.00M 10-Q · filed 2021-05-10 | $2.60M derived: sum of 2 quarters · filed 2022-03-01 | $3.62M derived: sum of 3 quarters · filed 2022-03-01 | $4.15M derived: sum of 4 quarters · filed 2022-03-01 |
| 2019-12-31 | $598.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-01 | $1.62M derived: sum of 2 quarters · filed 2022-03-01 | $2.15M derived: sum of 3 quarters · filed 2022-03-01 | $2.52M 10-K · filed 2022-03-01 |
| 2019-09-30 | $1.02M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-09 | $1.55M derived: sum of 2 quarters · filed 2020-11-09 | $1.92M 10-Q · filed 2020-11-09 | $1.92M derived: sum of 4 quarters · filed 2021-03-01 |
| 2019-06-30 | $529.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-10 | $902.00K 10-Q · filed 2020-08-10 | $902.00K derived: sum of 3 quarters · filed 2021-03-01 | $902.00K derived: sum of 4 quarters · filed 2021-03-01 |
| 2019-03-31 | $373.00K 10-Q · filed 2020-05-11 | $373.00K derived: sum of 2 quarters · filed 2021-03-01 | $373.00K derived: sum of 3 quarters · filed 2021-03-01 | $373.00K derived: sum of 4 quarters · filed 2021-03-01 |
| 2018-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-01 | $0.00 derived: sum of 2 quarters · filed 2021-03-01 | $0.00 derived: sum of 3 quarters · filed 2021-03-01 | $0.00 10-K · filed 2021-03-01 |
| 2018-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-12 | $0.00 derived: sum of 2 quarters · filed 2019-11-12 | $0.00 10-Q · filed 2019-11-12 | |
| 2018-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-09 | $0.00 10-Q · filed 2019-08-09 | ||
| 2018-03-31 | $0.00 10-Q · filed 2019-05-10 | |||
| 2017-12-31 | $0.00 10-K · filed 2020-03-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 | |
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |